science wire

Pharmacology - Health - 02.06.2019

Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer shows positive data in those with liver metastases
Data will be presented at the American Society of Clinical Oncology (ASCO) annual meeting on 2 June 2019 Roche today announced positive additional results of a prespecified exploratory analysis from

Health - Pharmacology - 01.06.2019

Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer (HR=0.712; p=0.00973) After a median of 42 months follow-up, the survival rate was 70&pe

Health - Pharmacology - 01.06.2019

Adding ribociclib to hormone therapy extends lives of women with most common breast cancer
A UCLA-led study has found that using a drug called ribociclib in combination with a common hormone therapy may help premenopausal women with the most common type of breast cancer live longer than if they only receive the hormone therapy. Ribociclib is considered a cyclin-dependent kinase inhibitor that works by blocking the activity of proteins called cyclin-dependent kinase 4/6 enzymes, which promote cell division and cancer growth.

Pharmacology - Health - 30.05.2019

Novartis’ phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthma
Low dose QMF149 (indacaterol acetate and mometasone furoate) demonstrated both statistically significant and clinically meaningful improvements in lung function and asthma control compared to inhaled

Health - Pharmacology - 29.05.2019

Health - Pharmacology - 24.05.2019

FDA approves Novartis Piqray - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
Piqray (alpelisib, formerly BYL719) plus fulvestrant nearly doubled median PFS (11.0 vs 5.7 months) in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation compared to fulve

Health - Pharmacology - 24.05.2019

AveXis Announces Innovative Zolgensma Gene Therapy Access Programs for US Payers and Families
One-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA   Annualized cost of Zolgensma is USD 425,000

Health - Pharmacology - 24.05.2019

AveXis receives FDA approval for Zolgensma , the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2 ,   Zolg

Health - Pharmacology - 24.05.2019

EPFL spin-off Bicycle Therapeutics floats on Nasdaq

Pharmacology - Health - 23.05.2019

Pharmacology - Health - 22.05.2019

Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
New inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate - IND/GLY/MF) was superior to the standard of care (long-acting beta-agonist/inhaled c

Health - Pharmacology - 21.05.2019

Bern Center for Precision Medicine inaugurated
The Bern Center for Precision Medicine (BCPM) of the University of Bern and Inselspital, University hospital of Bern, were officially opened today in the presence of Director of Education Christine Häsler.

Pharmacology - Health - 21.05.2019

Treating muscular disease - Santhera and Biozentrum join forces
Santhera Pharmaceuticals and the University of Basel's Biozentrum announce their collaboration to advance gene therapy research for the treatment of congenital muscular dystrophy.

Pharmacology - 21.05.2019

Pharmacology - Health - 16.05.2019

Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders
Overall survival results from MONALEESA-7 with Kisqali (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO   Primary results of

Health - Pharmacology - 16.05.2019

Roche’s personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents
Phase I/II study of entrectinib, an investigational medicine, showed responses in all paediatric tumour types harbouring neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kina

Pharmacology - Health - 16.05.2019

Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia
Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta off

Pharmacology - Chemistry - 15.05.2019

German Research Foundation approves new Research Training Group

Health - Pharmacology - 14.05.2019

New Roche test aids clinicians in accelerating tuberculosis diagnosis and treatment by detecting antimicrobial resistance within the world’s leading cause of infectious disease deaths
New tests on cobas 6800/8800 systems provide clinicians information to help speed treatment and reduce the spread of infection Rising challenge of drug resistance compounds the tuberculosis global health crisis Mycobacteria test menu allows detection of tuberculosis, drug resistant tuberculosis and nontuberculous mycobacteria infections from single patient sample Roche today announced the CE-IVD launch of the cobas MTB-RIF/INH test to detect resistance to antibiotics within tuberculosis DNA.

Health - Pharmacology - 14.05.2019

Major UK clinical trial for Group B Strep screening in pregnant women announced
A landmark clinical trial is aiming to improve the prevention of potentially life-threatening infection caused by group B Streptococcus in newborn babies in the UK.

Pharmacology - Health - 10.05.2019

Novartis data at AAN show Gilenya is the first and only disease-modifying therapy with proven superiority versus glatiramer acetate in relapsing remitting MS
Full results from the ASSESS study demonstrate patients with relapsing remitting multiple sclerosis (RRMS) taking Gilenya  (fingolimod) 0.5mg had significantly fewer relapses than patients taking glatiramer acetate 20mg Gilenya showed significant superiority versus glatiramer acetate in other key measures of disease activity, such as brain lesions   There were more discontinuations on glatiramer acetate compared to Gilenya reinforcing Gil

Health - Pharmacology - 10.05.2019

Roche to present new data highlighting comprehensive approach to cancer care at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Study results across 17 medicines reflect our commitment to personalised care with advances in targeted therapies, immunotherapy, and diagnostics, data and analytics New pivotal data on fixed-duratio

Pharmacology - Health - 09.05.2019

Pharmacology - Health - 09.05.2019

Health - Pharmacology - 08.05.2019

Progesterone could increase live births in women with early pregnancy bleeding and a history of miscarriage
Research led by the University of Birmingham suggests that giving progesterone to pregnant women with early pregnancy bleeding and a history of miscarriage could increase their chances of having a baby. The PRISM trial , funded by the National Institute for Health Research (NIHR) and co-ordinated by Birmingham Clinical Trials Unit in collaboration with Tommy's National Centre for Miscarriage Research, is the largest ever trial of its kind and involved 4,153 pregnant women who presented with early pregnancy bleeding.

Pharmacology - 08.05.2019

New approach to drug discovery could lead to personalised treatment of neuropsychiatric disorders

Pharmacology - Health - 08.05.2019

Novartis data at AAN show Mayzent’s positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS
Data from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent (siponimod) had a meaningful benefit on cognitive processing speed (CPS) for these patients   Impairment in cognitive function, one of the most disabling aspects of MS, affects 50-70% of patients and is more severe in patients with SPMS   EXPAND findings demonstrate that SPMS patients treated earlier in the cou

Health - Pharmacology - 07.05.2019

New AveXis data at AAN showed long-term durability of Zolgensma in patients with spinal muscular atrophy (SMA) Type 1
Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial   Mean age of follow-up since dosing with Zolge

Innovation / Technology - Pharmacology - 07.05.2019

’Adopt-a-hive’ scheme for schools
A leading Wales learning technology company, Aspire 2Be, is teaming up with Cardiff University to encourage school pupils to learn about the importance of bees and beekeeping.

Health - Pharmacology - 07.05.2019

Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians evaluate and discuss early signs of progression to secondary progressive MS
Up to 80% of relapsing remitting MS (RRMS) patients transition to secondary progressive MS (SPMS) , a stage of the disease leading to continuous functional decline, which is often undiagnosed or diagnosed only retrospectively   Data presented at AAN show that MSProDiscuss TM , a scientifically-validated digital tool, was able to provide information to support differentiation between RRMS and SPMS with high sensitivity and specificity   These fin

Pharmacology - Health - 06.05.2019

FDA approves Roche’s Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer The

Pharmacology - Health - 02.05.2019

Novartis to highlight extensive long-term safety and efficacy data of Aimovig across the spectrum of migraine at AAN
After long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average   Separate study showed

Health - Pharmacology - 02.05.2019

Yale joins NIH research network aimed at improving maternal-fetal health
High-impact research that makes its way into clinical practice is made possible thanks to large-scale multicenter clinical trials.

Pharmacology - 01.05.2019

Pharmacology - Health - 30.04.2019

New data at AAN reinforce Novartis commitment to transforming the lives of people of all ages who live with neurological conditions
Novartis leads the way at AAN with 53 abstracts, showcasing its broad portfolio of transformative medicines and innovative solutions for people living with spinal muscular atrophy (SMA), multiple scl

Health - Pharmacology - 30.04.2019

Pharmacology - Life Sciences - 30.04.2019

Researchers create the first maps of two melatonin receptors essential for sleep
Share This Article The behavior of humans and all animals is governed by a variety of natural cycles.

Pharmacology - Health - 29.04.2019

New Roche data at the 2019 AAN Annual Meeting showcase breadth and promise of neuroscience portfolio
Risdiplam data from Part 1 of pivotal FIREFISH study show infants with Type 1 spinal muscular atrophy achieve key motor milestones and improved survival after one year of treatment New analyses in re

Health - Pharmacology - 25.04.2019

Pharmacology - Health - 24.04.2019

Health - Pharmacology - 24.04.2019

Two Decades of Swiss Leadership for New Malaria Medicines
On World Malaria Day 2019, Swiss organizations look back on a long history of successful public-private collaboration for new malaria medicines.

Pharmacology - Business / Economics - 24.04.2019

Pharmacology - Health - 23.04.2019

Health - Pharmacology - 23.04.2019

Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients eligible for targeted therapy
Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year, and more than 620,000 people will die from the disease.

Pharmacology - Health - 18.04.2019

University of Birmingham SCRIPT eLearning programme advocated for prescribers to ensure the safer use of medicines and reduce errors
Healthcare safety investigators advocate that all professionals responsible for prescribing use an online learning programme developed by the University of Birmingham.

Health - Pharmacology - 17.04.2019

Sniffles and sneezes: A Q&A about allergies with Dr. Ryan Steele
With allergy season upon us, YaleNews spoke to Dr. Ryan Steele , instructor of clinical medicine at Yale School of Medicine, about the current season, prevention, treatments, and other facts allergy sufferers need to know.

Pharmacology - Health - 15.04.2019

Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
By 2020, over 1.5 million people in the US are likely to have wet AMD, the leading cause of blindness in industrialized countries   Filing is based on Phase III data from the HAWK and HARRIER

Pharmacology - Health - 15.04.2019

Innovative Medicines Initiative Launches Translational Safety Biomarker Pipeline Project
The University of Zurich coordinates a worldwide research project that focuses on the development of new biomarkers.

Pharmacology - Health - 12.04.2019

Successful home-based heart rehabilitation programme rolled out
A new rehabilitation programme which helps heart failure patients achieve better quality of life from the comfort of their own homes will now be rolled out at four NHS centres across the UK. Research has found that the Rehabilitation Enablement in Chronic Heart Failure (REACH-HF) programme, developed by a collaboration led by the University of Exeter and the Royal Cornwall Hospitals NHS trust, significantly improved quality of life.

Pharmacology - Health - 12.04.2019

’Pharmabees’ to make honey cosmetics
Cardiff University is joining forces with a North Wales company to produce a new brand of natural cosmetics, Celtic Wellbeing.